Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.

Date publication

juillet 2018

Journal

Annals of surgical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric

Tous les auteurs :
Malgras B, Gayat E, Aoun O, Dico RL, Eveno C, Pautrat K, Delhorme JB, Passot G, Marchal F, Sgarbura O, Ferron G, Goéré D, Andre T, Pocard M,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29978366

Résumé

The introduction of cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) improved the prognosis of selected patients with peritoneal mesothelioma (PM).

Mots clés

Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Chemotherapy, Cancer, Regional Perfusion, mortality, Cisplatin, administration & dosage, Combined Modality Therapy, Doxorubicin, administration & dosage, Erythrocyte Transfusion, mortality, Female, Follow-Up Studies, Humans, Hyperthermia, Induced, mortality, Irinotecan, administration & dosage, Lung Neoplasms, mortality, Male, Mesothelioma, mortality, Middle Aged, Mitomycin, administration & dosage, Oxaliplatin, administration & dosage, Peritoneal Neoplasms, mortality, Prognosis, Prospective Studies, Survival Rate

Référence

Ann. Surg. Oncol.. 2018 Jul 5;: